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Complexes [Pt(2Bz4oT)Cl], [Pt(2Bz4mT)Cl], and [Pt(2Bz4pT)Cl] were prepared with N(4)-ortho-
(H2Bz4oT), N(4)-meta-(H2Bz4mT), and N(4)-para-(H2Bz4pT) tolyl-2-benzoylpyridine-derived thiosemi-
carbazones. The thiosemicarbazones exhibited moderate anti-proliferative activity against HepG2 (hep-
atoma) and UACC-62 (melanoma) cancer cell lines, but showed high anti-proliferative effect against A431
(epithelial carcinoma) cancer cell lines. Upon coordination to platinum(II) the anti-proliferative activity
decreases in all cases. The cytotoxicity of the previously prepared palladium(II) analogues [Pd(2Bz4oT)Cl],
[Pd(2Bz4mT)Cl], and [Pd(2Bz4pT)Cl] was also investigated. As in the case of the platinum(II) complexes,
coordination to palladium(II) did not lead to activity improvement. Investigations on the mechanism of
cytotoxic action against A431 cells revealed that [Pd(2Bz4oT)Cl] induced DNA fragmentation and apop-
tosis while H2Bz4oT did not present this effect. The high anti-proliferative effect of the thiosemicarba-
zones and [Pd(2Bz4oT)Cl] against A431 cells, together with the pro-apoptotic effect of [Pd(2Bz4oT)Cl]
suggests that these compounds have potential as chemotherapeutic drug candidates.
 2010 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
The antitumoral properties of cis[diamminedichloroplatinum(II)],
cisplatin, are now well documented. Cisplatin is used to treat both
solid and disseminated tumors and has been shown to be effective
against virally-induced, chemically-induced and transplantable
tumors [1]. Cisplatin shows a great synergy with many other che-
motherapeutic drugs and is widely employed in the treatment of
testicular, ovarian and breast cancer. However, the toxic side effects
associated with cisplatin, which are particularly severe at the level
of renal function, represent a major drawback in its therapeutic
employment [1]. Moreover, the clinical utility of cisplatin and the
second generation platinum drugs is limited to a relatively narrow
range of tumors, because of primary resistance and the develop-
ment of resistance secondary to the initial treatment [2].
Hence unconventional platinum(II) complexes with different
organic ligands were designed as a strategy to overcome resistance
to cisplatin and its analogs [3]. Also, palladium(II) complexes withx: +55 31 3499 5700.
evier OA license.a variety of ligands were obtained and assayed against human
tumor cell lines and cisplatin-resistant tumor cell lines [4,5].
Thiosemicarbazones and their metal complexes are very prom-
ising compounds which present a wide range of pharmacological
applications as antimicrobial, antiparasital, antitumoral and antivi-
ral agents [6]. In many circumstances the pharmacological activity
of thiosemicarbazones increases upon coordination to metal ions
[6–9].
It has been shown that palladium(II) and platinum(II)
complexes with thiosemicarbazones are active against cisplatin-
resistant human cancer cell lines, probably because their mode
of action involves inter-strand crosslinks with DNA, while intra-
strand crosslinks is the major coordination mode of cisplatin
[10,11].
We demonstrated that 2-benzoylpyridine-derived thiosemicar-
bazones and their palladium(II) and tin(IV) complexes present
cytotoxic activity against MCF-7, TK-10 and UACC-62 human
tumor cell lines and are able to induce cell death by apoptosis
[12,13].
Our recent investigation on N(4)-tolyl-thiosemicarbazones
revealed that upon coordination of 2-acetylpyridine- and 2-benzo-
ylpyridine-derived N(4)-tolyl-thiosemicarbazones to copper(II) the
Fig. 1. General structure of the conﬁgurational isomers of 2-benzoylpyridine N(4)-
ortho-, (H2Bz4oT), N(4)-meta-(H2Bz4mT), and N(4)-para-(H2Bz4pT) tolyl-
thiosemicarbazones.
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strated that N(4)-ortho-(H2Bz4oT), N(4)-meta-(H2Bz4mT) and
N(4)-para-(H2Bz4pT) tolyl-thiosemicarbazones derived from
2-benzoylpyridine are highly cytotoxic against Jurkat, HL60 and
the resistant HL60.Bcl-XL leukemia cell lines at nanomolar
concentrations, but much less cytotoxic to HepG2 human hepa-
toma cells [14].
In the present work H2Bz4oT, H2Bz4mT, and H2Bz4pT (see
Fig. 1) and their platinum(II) complexes have been evaluated for
their in vitro anti-proliferative activity against HepG2 (hepatoma),
UACC-62 (melanoma) and A431 (epithelial carcinoma) human can-
cer cell lines. For comparison purposes we also assayed the cyto-
toxicity of the palladium(II) complexes with the same ligands
against the same cell lineages.
The human epidermoid carcinoma cell line A431 is derived
from a human squamous carcinoma and expresses abnormally
high levels of the epidermal growth factor receptor (EGFR) [15].
EGFR signaling inhibition represents a highly promising arena for
the application of molecularly targeted cancer therapies, specially
as an important molecular target in epithelial malignancies [16].
UACC-62 is a human cancer cell line recommended by the Na-
tional Cancer Institute (NCI, USA) in screening studies for detection
of anti-proliferative compounds.
HepG2 cells present hepatocyte speciﬁc cell functions and were
chosen as a model of cytotoxicity of xenobiotics. Several studies
suggest that these cells have retained many characteristics of adult
hepatocytes, and therefore are a good tool to predict potential tox-
icity (mutagenicity and carcinogenicity) of compounds [17–20].2. Experimental
2.1. Materials and instrumentation
Partial elemental analyses were performed on a Perkin–Elmer
CHN 2400 analyzer. Infrared spectra were recorded on a Perkin–El-
mer FT-IR Spectrum GX spectrometer using CsI pellets; an YSI
model 31 conductivity bridge was employed for molar conductiv-
ity measurements; NMR spectra were obtained at room tempera-
ture with a Bruker DRX-400 Avance (400 MHz) spectrometer
using deuterated dimethyl sulfoxide (DMSO-d6) as the solvent
and tetramethylsilane (TMS) as internal reference. Splitting pat-
terns are designated as follows: s, singlet; d, doublet; t, triplet; q,
quartet; m, multiplet.2.2. Synthesis
2.2.1. Syntheses of N(4)-ortho-(H2Bz4oT), N(4)-meta-(H2Bz4mT), and
N(4)-para-(H2Bz4pT) tolyl-2-benzoylpyridine thiosemicarbazones
H2Bz4oT (1), H2Bz4mT (2), and H2Bz4pT (3) were prepared
according to previously reported procedures [7,8].
2.2.2. Synthesis of platinum(II) and palladium(II) complexes with
N(4)-ortho-(H2Bz4oT), N(4)-meta-(H2Bz4mT) and N(4)-para-
(H2Bz4pT) tolyl-2-benzoylpyridine thiosemicarbazones
The platinum(II) complexes were prepared by mixing the de-
sired ligand in ethanol with an aqueous solution of K2PtCl4 in equi-
molar amounts (1 mmol). The reaction mixture was kept under
reﬂux for 2 h. The solids which precipitate were ﬁltered off and
washed with ethanol and ether, and dried.
The synthesis of the palladium(II) complexes with the same li-
gands have been reported previously [14].
2.2.2.1. [Pt(2Bz4oT)Cl] (4). Maroon solid. Yield: 63%. Anal. Calc. for
C20H17ClN4PtS (575.97): C, 41.71; H, 2.97; N, 9.73. Found: C,
41.50; H, 2.71; N, 9.86%. Molar conductivity (1  103 mol L1
DMF): 1.0X1 cm2 mol1. IR (KBr, CsI/Nujol, cm1): m(C@N)
1615m, m(C@S) 777w, q(py) 701w, m(M–N) 380w, m(M–S) 343m,
m(M–Npy) 257m, m(M–Cl) 303w. The main signals in 1H NMR
(DMSO-d6): d (ppm) = 8.87 (1H, d, H(6)), 7.71 (1H, d, H(5)), 8.05
(1H, t, H(4)), 7.22 (1H, d, H(3)), 9.92 (1H, s, N(4)H). 13C NMR
(DMSO-d6): d (ppm) = 169.51, C8@S; 142.86, C7@N; 147.60, C6;
126.66, C5; 141.64, C4; 127.61, C3; 158.13, C2.
2.2.2.2. [Pt(2Bz4mT)Cl] (5). Brown solid. Yield: 94%. Anal. Calc. for
C20H17ClN4PtS (575.97): C, 41.71; H, 2.97; N, 9.73. Found: C,
41.39; H, 3.03; N, 9.78%. Molar conductivity (1  103 mol L1
DMF): 16X1 cm2 mol1. IR (KBr, CsI/Nujol, cm1): m(C@N)
1595m, m(C@S) 781m, q(py) 642w, m(M–N) 384w, m(M–S) 350m,
m(M–Npy) 278m, m(M–Cl) 302w. The main signals in 1H NMR
(DMSO-d6): d (ppm) = 8.92 (1H, d, H(6)), 7.77 (1H, H(5)), 8.10
(1H, t, H(4)), 7.60 (1H, d, H(3)), 10.29 (1H, s, N(4)H). 13C NMR
(DMSO-d6): d (ppm) = 178.25, C8@S; 158.06, C7@N; 146.77, C6;
127.10, C5; 140.72, C4; 127.19, C3; 159.12, C2.
2.2.2.3. [Pt(2Bz4pT)Cl] (6). Brown solid. Yield: 68%. Anal. Calc. for
C20H17ClN4PtS (575.97): C, 41.71; H, 2.97; N, 9.73. Found: C,
41.54; H, 3.01; N, 9.58%. Molar conductivity (1  103 mol L1
DMF): 14.5X1 cm2 mol1. IR (KBr, CsI/Nujol, cm1): m(C@N)
1603m, m(C@S) 753w, q(py) 682w, m(M–N) 384w, m(M–S) 350w,
m(M–Npy) 280m, m(M–Cl) 304w. The main signals in 1H NMR
(DMSO-d6): d (ppm) = 8.88 (1H, d, H(6)), 7.72 (1H, t, H(5)), 8.07
(1H, t, H(4)), 7.37 (1H, d, H(3)), 9.93 (1H, s, N(4)H. 13C NMR
(DMSO-d6): d (ppm) = 179.68, C8@S; 141.68, C7@N; 149.26, C6;
126.64, C5; 141.56, C4; 127.58, C3; 160.55, C2.
2.3. X-ray crystallography
Crystals suitable for X-ray diffraction were obtained from slow
evaporation of 4 in 1:9 DMSO/acetone. Crystal of [Pt(2Bz4oT)Cl]
DMSO (4a) was mounted on a glass ﬁber and used for data
collection. X-ray diffraction data collection was performed on a
Oxford-DiffractionGEMINI-Ultra diffractometer (LabCri) using graph-
ite-Enhance SourceMo Ka radiation (k = 0.71069 Å) at 293(2) K. Data
integration and scaling of the reﬂections were performed with the
CRYSALIS suite [21]. Final unit cell parameters were based on the
ﬁtting of all reﬂections positions. The structure was solved by direct
methods using the program SHELXS-97 [22] and reﬁned by full-matrix
least-squares techniques against F2 using SHELXL-97 [23].
Positional and anisotropic atomic displacement parameters
were reﬁned for all non hydrogen atoms. The solvation DMSO in
Table 1
Crystal data and structure reﬁnement for [Pt(2Bz4oT)Cl]DMSO (4a).
Identiﬁcation code (4a)
Empirical formula PtC20H17N4SClC2OS
Formula weight 654.10
Crystal system monoclinic
Space group P21/c
Unit cell dimensions
a (Å) 11.8140(4)
b (Å) 16.6548(3)
c (Å) 13.2376(4)
b () 114.803(4)
Volume (Å3) 2364.36(12)
Z 4
Dcalc (mg/m3) 1.838
Absorption coefﬁcient (mm1) 6.246
F(0 0 0) 1272
h Range for data collection 2.98–26.37
Limiting indices () 13 6 h 6 14
20 6 k 6 18
16 6 l 6 16
Reﬂections collected/unique 12246/4834 (Rint = 0.0315)
Completeness to h = 26.37 99.9%
Data/restraints/parameters 3378/0/291
Goodness-of-ﬁt on F2 0.808
Final R indices [I > 2r(I)] R1 = 0.0230, wR2 = 0.0318
R indices (all data) R1 = 0.0433, wR2 = 0.0333
Largest difference in peak and hole (e A3) 0.602 and 0.799
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reﬁned resulting in the ratio of 61.5/38.5. The hydrogen atoms
were located in difference maps and included as ﬁxed contribu-
tions riding on attached atoms. Criteria of a satisfactory complete
analysis were the ratios of rms shift to standard deviation less than
0.001 and no signiﬁcant features in ﬁnal difference maps. Molecu-
lar graphics were obtained from ORTEP [24]. A summary of the crys-
tal data, experimental details and reﬁnement results are listed in
Table 1.2.4. In vitro cytotoxicity studies (assays with human cancer cell lines)
2.4.1. Materials
Cisplatin, methylthiazoletetrazolium (MTT), RPMI-1460, and
L-glutamine were purchased from Sigma Chemicals. Antibiotic/
antimicotic solution was purchased from GIBCO BRL, Grand Island,
NY.2.4.2. Cell lines
Human liver tumor cells, HepG2, and A431, were obtained from
the American Type Culture Collection (Manassas, VA). Human mel-
anoma cell line UACC-62, was obtained from the NCI anticancer
cell line panel of the National Cancer Institute-Division of Cancer
Treatment and Diagnosis repository, National Cancer Institute,
Frederick, MD. All lineages were maintained in the logarithmic
phase of growth in RPMI 1640 supplemented with 5% fetal bovine
serum (GIBCO BRL, Grand Island, NY); 100 U/mL penicillin and
100 lg/mL streptomycin (GIBCO BRL, Grand Island, NY) and fung-
izon. All cultures were maintained at 37 C in a humidiﬁed incuba-
tor with 5% CO2 and 95% air. The media were changed twice weekly
and they are regularly examined.2.4.3. Anti-proliferative assay
For the cytotoxicity evaluation, HepG2 were detached from the
culture ﬂasks by addition 1 mL of 0.05% trypsin–EDTA (GIBCO BRL,
Grand Island, NY). After counting, dilutions were made to give
appropriate cell densities for inoculating onto the microtiter plates.
Cells were inoculated in a volume of 100 lL/well at densities of
40 000 cells.UACC-62 and A431 cells were inoculated at 10 000 cells of per
well. The plates were pre-incubated for 24 h at 37 C to allow adap-
tation of cells prior to the addition of the test compounds. Freshly
prepared solutions of the different substances were tested at
50 lM. Subsequently, the plates were incubated for 48 h in an
atmosphere of 5% CO2 and 100% relative humidity. Control groups
included treatment with 0.1% DMSO (negative control) and 50 lM
of cisplatin (positive control). Cell viability was estimated by mea-
suring the rate of mitochondrial reduction of MTT (3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). All compounds
were dissolved in dimethyl sulfoxide (DMSO), prior to dilution.
All compounds were tested in triplicate.
2.4.4. In vitro cell viability assay – MTT assay
The MTT assay is a standard colorimetric assay, which measures
reduction of MTT to formazan by mitochondrial dehydrogenases in
living cells, with production of a purple color [25]. The yellow tet-
razolium salt (MTT) is reduced in metabolically active cells to form
insoluble purple formazan crystals, which are solubilized by the
addition of a solvent. The color can then be quantiﬁed by spectro-
photometric means. The samples are read using an ELISA plate
reader at a wavelength of 570 nm. The amount of purple color pro-
duced is directly proportional to the number of viable cells.
Brieﬂy, for the ﬁnal 4 h of incubation 20 lL of MTT solution
(5 mg/mL in phosphate-buffered saline) were added to each well.
At the end of the incubation period the supernatant was removed
and 200 lL of 0.04 M HCl in isopropyl alcohol were added to dis-
solve the formazan crystal.
The optical densities (OD) were evaluated in a spectrophotom-
eter at 570 nm. Controls included drug-containing medium (back-
ground) and drug-free complete medium. Drug-free complete
medium was used as control (blank) and was treated in the same
way as the drug-containing media. Results were expressed as per-
centage of cell proliferation, comparing with 0.1% DMSO control
and were calculated as follows: cell proliferation (%) = (mean OD
treated mean OD background)/mean OD untreated cultured, i.e.
0.1% DMSO mean OD blank wells)  100. Interactions of com-
pounds and media were estimated on the basis of the variations
between drug-containing medium and drug-free medium to es-
cape from false-positive or false-negative [26].
2.4.5. DNA fragmentation assay
Cell cycle status and quantiﬁcation of DNA fragmentation
(hypodiploid DNA-content) was performed by propidium iodide
(PI) staining according to Nicolleti and colleagues [27]. Cells were
treated with the four compounds (50 lM) in a 5% CO2/95% air-
humidiﬁed atmosphere at 37 C for 24 h. After drug incubation,
the cells were centrifuged and resuspended in hypotonic ﬂuoro-
chrome solution – HFS (50 lg/mL propidium iodide – PI in 0.1% so-
dium citrate plus 0.1% Triton X-100). The samples in HFS were
incubated at 4 C during 4 h and immediately taken to ﬂow cytom-
eter. The PI ﬂuorescence of 20 000 individual nuclei was measured
using a FACScalibur ﬂow cytometer (Becton Dickinson Immunocy-
tometry Systems, San Jose, California). Data analysis was per-
formed with FLOWJO software (TreeStar Inc., CA, USA).
2.4.6. Statistical analysis
All experiments were performed at least three replicates per
compound and results shown are the average of three independent
experiments. Data are represented as mean ± SEM. Signiﬁcance
was tested by Student’s t-test.
2.5. Studies of interactions with supercoiled plasmid DNA
Agarose gel electrophoresis, was carried out to identify the
modiﬁcations resulting from the DNA-complexes interaction. Thus,
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incubated with compounds (1, 4, and 7) at the same concentration
(75 lM) in Tris–HCl buffer (NaCl 50 mM, Tris–HCl 5 mM, pH 7.2).
The mixture was incubated at 37 C for 24 h [28]. Thereafter, the
reactions were quenched by adding 5 lL of a loading buffer solu-
tion (50 mmol L1 Tris, pH 7.2, 0.01% bromophenol blue, 50% glyc-
erol, and 250 mmol L1 EDTA). The samples were analyzed by 0.8%
agarose gel electrophoresis in 0.5X TBE buffer for 1 h at 75 mV. The
gel was stained after electrophoresis in 0.5X TBE buffer with
2.5 lg mL1 ethidium bromide for 15 min and visualized by UV
light.3. Results and discussion
Microanalyses and molar conductivity data suggest the forma-
tion of [Pt(L)Cl] complexes with all thiosemicarbazones.
The m(C@N) stretching vibration of the thiosemicarbazones at
1583–1594 cm1 in the infrared spectra shifts to 1595–1615 cm1
in the complexes, indicating coordination of the imine nitrogen
[7–9,12–14]. The absorption at 846–849 cm1 in the spectra of
the free bases, attributed to the m(C@S) vibration, shifts to 753–
781 cm1 in the spectra of the complexes, indicating coordination
through a thiolate sulfur [7–9,12–14]. Absorptions at 257–280,
380–384, 343–350, and 302–304 cm1 in the spectra of the com-
plexes were attributed to the m(Pt–Npy), m(Pt–N), m(Pt–S), and
m(Pt–Cl) vibrations, respectively [29]. Hence the infrared spectra
indicate coordination through the N–N–S chelating system. A chlo-
ride ion occupies the fourth coordination site.
The NMR spectra of the thiosemicarbazones and their plati-
num(II) complexes were recorded in DMSO-d6 because this is the
only solvent which dissolves all ligands and complexes. The 1H res-
onanceswere assigned on the basis of chemical shifts andmultiplic-
ities. The carbon type (C, CH) was determined by using distortion
less enhancement by polarization transfer (DEPT135) experiments.Fig. 2. Molecular plot of [Pt(2Bz4oT)Cl]DMSO (4a) showing the labeling scheme ofThe assignments of the protonated carbons were made by 2D het-
ero-nuclear multiple quantum coherence experiments (HMQC).
All 1H and 13C signals of the thiosemicarbazones are duplicated,
according to the existence of the Z and E conﬁgurational isomers in
solution. In the ﬁrst N3–H is hydrogen-bonded to the pyridine
nitrogen, while in the latter N3–H is hydrogen-bonded to the sol-
vent [7–9,12–14]. Only one signal was observed for all hydrogens
and carbons in the spectra of the complexes. The signal of N3–H
is absent in the spectra of 4–6, according to deprotonation and
formation of an anionic ligand. Upon coordination the signals of
the pyridine hydrogens as well as those of N4–H undergo signiﬁ-
cant shifts, suggesting coordination of the pyridine nitrogen and
of the sulfur [7–9,12–14]. Variations occur in the 13C NMR spectra
for the signals of C8–S, C7–N and the pyridine carbons, in
accordance with coordination of the sulfur, the imine nitrogen
and the hetero-aromatic nitrogen, leading to compounds in which
the thiosemicarbazone adopts the E conﬁguration in relation to the
C7–N2 bond [7–9,12–14].3.1. X-ray crystallography
In the [Pt(2Bz4oT)Cl]DMSO (4a) crystals the metal coordination
number is four and the thiosemicarbazone adopts the EZ confor-
mation in relation to the C7@N2 and C8@N3 bonds (see Fig. 2).
The thiosemicarbazone is attached to the metal centre through
the Npy–N–S coordination system and a chloride ion occupies the
fourth coordination position.
The crystal structure of the palladium analogue of complex (4a),
[Pd(Bz4oT)Cl]DMSO, has been previously determined by some of
us [14]. Selected bond distances and angles in both structures are
reported in Table 2 for the sake of comparison.
The C8–S bond distance is 1.753(4) Å in 4a, which is closer to
the observed values for C–S single bonds [12–14]. In the free
thiosemicarbazone this bond has a predominantly double bondthe non-H atoms and their displacement ellipsoids at the 50% probability level.
Table 2
Selected bonds distances (Å) and angles () for [Pt(2Bz4oT)Cl]DMSO (4a) and
[Pd(2Bz4oT)Cl]DMSO.
Atoms [Pt(2Bz4oT)Cl]DMSO (4a) [Pd(2Bz4oT)Cl]DMSO
Distances (Å)
M–N2 1.945(2) 1.952(3)
M–N1 2.046(2) 2.069(4)
M–S1 2.2461(8) 2.242(1)
M–Cl1 2.2963(9) 2.290(1)
S1–C8 1.753(3) 1.751(4)
C2–C7 1.463(4) 1.469(6)
N2–C7 1.314(4) 1.307(5)
N2–N3 1.381(3) 1.379(5)
N3–C8 1.315(4) 1.317(5)
N4–C8 1.353(4) 1.355(6)
N4–C9 1.425(4) 1.439(6)
Angles ()
N1–C2–C7 115.8(3) 115.6(4)
N2–C7–C2 113.8(3) 115.1(4)
C7–N2–N3 119.2(3) 119.5(4)
N2–N3–C8 111.6(3) 111.1(4)
N4–C8–N3 118.2(3) 118.3(4)
C8–N4–C9 127.1(3) 126.8(4)
N3–C8–S1 125.7(2) 125.9(3)
N2–M–N1 80.73(10) 81.0(1)
N1–M–S1 166.14(8) 166.1(1)
N2–M–S1 85.41(8) 85.1(1)
N1–M–Cl1 97.28(8) 97.9(1)
N2–M–Cl1 177.08(8) 177.4(1)
S1–M–Cl1 96.57(3) 96.03(5)
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formation of a highly delocalized system involving the thiosemi-
carbazone chain and the aromatic ring, and C–S acquires a predom-
inantly single bond character.
As expected, most bond distances and angles in the thiosemi-
carbazones chain are similar in the two complexes. Even the metal
bond distances, such as M–N, M–S, and M–Cl are alike. This is due
to the small difference in the radius of platinum(II) and palla-
dium(II) in square-planar coordination compounds – Pt(II) = 0.74 Å
and Pd(II) = 0.78 Å [30].
3.2. Cytotoxic activity against human tumor cells
The anti-proliferative activities of the free thiosemicarbazones
(1–3) and their complexes (4–6) were assayed on HepG2 human
hepatoma, UACC-62 melanoma and A431 human epithelial carci-
noma cells. Fig. 3 shows the percentage of cell proliferation in
the presence of the thiosemicarbazones and their platinum(II)
complexes (4–6), along with data for the palladium(II) analoguesFig. 3. Cytotoxic effect of thiosemicarbazones 1–3 and complexes 4–9 on HepG2, A431, a
cell proliferation/cell survival was measured by the MTT assay as described in Methods
control (cells treated with DMSO 0.1%). Representative data of at least three independen[Pd(2Bz4oT)Cl] (7), [Pd(2Bz4mT)Cl] (8), and [Pd(2Bz4pT)Cl] (9).
The cytotoxic activity of the thiosemicarbazones and complexes
(7–9) was previously studied against leukemia cells and against
HepG2 cells [14], but their activity against UACC62 and A431 solid
tumor cell lines is reported for the ﬁrst time in the present paper.
The anti-proliferative effect of the compounds was evaluated by
measuring the levels of cell proliferation after incubation of cells
with the test samples, using the MTT colorimetric assay, which
evaluates the capacity of the mitochondrial enzyme succinate
dehydrogenase of viable cells to reduce 3-(4,5-dimethythiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan crystals.
The results are expressed as percentage of cell proliferation com-
pared with cell control (cell treated with vehicle, DMSO 0.1%)
(Fig. 3). Cisplatin, a reference drug currently used on clinic, was as-
sayed as positive control.
Cell type-speciﬁc susceptibility differences could be observed
after incubation with the different compounds. The proliferation
inhibition of HepG2 and UACC-62 cells by the thiosemicarbazones
at the maximum concentration of 50 lM was 15–60%, while inhi-
bition of A431 cells’ growth was 90%. Cisplatin inhibited 50% of
A431 cells’ proliferation at the same concentration. The anti-prolif-
erative activity of the three thiosemicarbazones against UACC-62
cells was comparable, suggesting that the position of the tolyl
group does not have inﬂuence on cytotoxicity. Similarly, the posi-
tion of the tolyl group did not inﬂuence cytotoxicity against A 431
cells. In contrast the meta-tolyl derivative exerted higher anti-pro-
liferative effect against HepG2 cells than its ortho and para-tolyl
analogues.
All platinum(II) complexes exerted lower anti-proliferative
activity than the free thiosemicarbazones against all cell lineages.
Similarly, the palladium(II) complexes exerted comparable or low-
er activity than the parent thiosemicarbazones against all cell lin-
eages, but were more cytotoxic than the platinum(II) analogues. No
signiﬁcant differences were observed in cytotoxicity against all cell
lineages among complexes 4–6. Complex 7 exerted higher cyto-
toxic effect against HepG2 cells and all complexes 7–9 exerted sim-
ilar effect against UACC-62 cells. Interestingly, the order of
cytotoxicity against A431 cells was 7 > 8 > 9. Cytotoxicity of com-
plex 7 was similar to that of cisplatin.
In a previous work we demonstrated that this same family of
thiosemicarbazones is highly cytotoxic against leukemia cells and
that upon coordination to palladium(II) activity decreases, like in
the present case [14].
Other groups reported an effect of increased cytotoxic activity
upon coordination of thiosemicarbazones to palladium(II)
[10,11]. However, in this case bidentate thiosemicarbazones were
employed, which lead to the formation of complexes with twond UACC-62 cell lines. Cells were treated with compounds (50 lM) for 48 h and the
. Data are expressed as mean ± SEM of percentage of cell proliferation compared to
t experiments performed in triplicate.
Fig. 4. Agarose gel electrophoresis of pGEM-T plasmid DNA treated with
compounds 1, 4, 7, K2PtCl4 (sPt), and K2PdCl4 (sPd) (75 lM) in Tris–HCl buffer
(NaCl 50 mM, Tris–HCl 5 mM, pH 7.2) incubated at 37 C for 24 h.
Fig. 5. DNA fragmentation induced by ligand (1) and complex (7) in A431 cells.
A431 cells were incubated with 50 lM of each compound, at 37 C in a 5% CO2
atmosphere for 24 h. DNA content was assessed by ﬂow-cytometric analysis of cells
labeled with propidium iodide. Each data represents SEM ± SD from two different
experiments (*P < 0.05, Student’s t-test).
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leased in order for the metal to bind to DNA forming inter-strand
crosslinks.
Like in the case of leukemia cells [14] we may suggest that the
lower activity of the platinum(II) and palladium(II) complexes as
compared to the activity of the free thiosemicarbazones against
the three solid tumor cell lines is probably due to the presence of
a tridentate ligand together with only one labile chloride in the
metal coordination sphere to be released allowing the metal to
bind to DNA.3.3. Studies of interactions with supercoiled plasmid DNA
The effect of 4 and 7 on DNA conformation was evaluated by the
electrophoretic mobility of the plasmid pGEM-T after association
with the complexes. At the employed concentration (75 lM) the
compounds did not alter the electrophoretic mobility of DNA
(Fig. 4). Ligand 1 did not modify the electrophoretic mobility of
DNA as well.
Hence our investigation on the interaction of 1, 4, and 7 with
DNA revealed either that these compounds do not interact with
the DNA bases or that interaction, if it occurs, does not lead to sta-
ble adducts at 75 lM. Interestingly, both starting salts interacted
with DNA in the employed conditions.
Since palladium(II) complexes are more labile than their plati-
num(II) congeners, release of the chloride from the metal coordina-
tion sphere occurs more easily in the ﬁrst case. The higher
cytotoxicity of the palladium(II) complexes suggests that release
of the chloride is probably involved in the mechanism of action
of these complexes.
Since the complexes present cytotoxic activity (but are less
cytotoxic than the corresponding ligands), we decided to further
investigate their mechanism of action. The mode of action of 1–3
probably occurs through inhibition of ribonucleoside diphosphate
reductase, the proposed mechanism of action of a(N)-heterocyclic
thiosemicarbazones [31–34].3.4. Studies of DNA fragmentation
To determine if the observed cytotoxic effects of ligands and
complexes were associated with other cell death mechanisms,
we evaluated the potential of these compounds to induce cell
death by apoptosis. We chose to investigate this effect in A431 cells
because this line was the most susceptible to both ligands and
complexes. Hence, we measured the percentage of subdiploid
DNA content in A431 cells in the presence of H2Bz4oT (ligand 1)
and complex (7), the most cytotoxic compounds in this lineage.
We used the method described by Nicoletti and colleagues
(1991) [27], which is based on the principle that the apoptoticcells, among other typical features, are characterized by DNA frag-
mentation and, consequently, loss of nuclear DNA content. Apopto-
tic nuclei appear as a broad hypodiploid DNA peak which is easily
discriminable from the narrow peak of cells with normal (diploid)
DNA content. This new rapid, simple and reproducible method is
useful for assessing apoptosis of speciﬁc cell populations.
Our results (Fig. 5) clearly demonstrate that complex (7), but
not its free thiosemicarbazone (1), induced an increase of subdip-
loid DNA content (DNA fragmentation) in A431 cells when com-
pared with vehicle (DMSO, 0.05%). Cisplatin was used as positive
control since it shows pro-apoptotic activity against several cancer
lineages.
These results suggested that the coordination of H2Bz4oT to
palladium(II) altered the thiosemicarbazone’s activity. In fact,
although ligand 1 did not show a pro-apoptotic effect, its complex
(7) presented pro-apoptotic activity. Although the screening MTT
experiment to quantify viability of A431 cells demonstrated simi-
lar effects for 1 and 7, analysis of DNA fragmentation clearly
showed that only 7 possesses pro-apoptotic activity.
Different cytotoxicity assays can give different results depend-
ing on the test agent used and the cytotoxicity assay employed
[35]. In this context, the DNA content analysis revealed different
proﬁles for 1 and 7 while the MTT assay indicated similar behavior
for both compounds. This can be attributed to the fact that MTT
evaluated the energetic function of mitochondria that is preserved
during the course of apoptosis. When the damage level of mito-
chondria is mild or moderate, mitochondria can still generate suf-
ﬁcient energy for initiation and execution of the apoptotic process
[36].
The increase of subdiploid DNA content (DNA fragmentation)
observed in A431 cells after treatment with 7 suggested that this
complex activates the apoptosis pathway. Thus although 1 and 7
presented a similar behavior in the electrophoresis assay, the more
sensitive DNA fragmentation assay showed completely distinct
behaviors for 1 and 7.
4. Conclusions
Our data demonstrate that the thiosemicarbazones and their
platinum(II) complexes inhibit the hepatoblastoma HepG2 cell line
proliferation at concentrations greater than 50 lM (Fig. 3). The
same is true for the previously studied palladium(II) complexes.
In vitro cytotoxicity assays have been recommended to predict
target-organ toxicity of a chemical in vivo [20]. HepG2 cells have
retained many characteristics of adult hepatocytes, and are there-
fore a good tool to predict potential toxicity of compounds [17–20].
Our results indicate that the thiosemicarbazones and their
K.O.S. Ferraz et al. / Polyhedron 30 (2011) 315–321 321platinum(II) and palladium(II) complexes have hepatotoxic proﬁles
similar to that of cisplatin.
The tumoral lineage A431, that expresses great levels of epider-
mal growth factor receptor (EGFR), has been used as a model to
screen compounds useful in the discovery of new anticancer
agents. Our results suggest that compounds 1–3 and 7 are highly
cytotoxic against A431 cells. Complex 7, in addition, is able to in-
duce cell death by apoptosis. Hence 1–3 and 7 could be useful to
treat squamous cell head and neck cancer, the seventh most com-
mon cause of cancer death worldwide whose incidence is rising
rapidly in developing countries [37,38].
The signiﬁcant cytotoxic effect of 1–3 and 7 against epithelial
carcinoma A431 cell lines together with their hepatotoxic proﬁle
similar to that of cisplatin, indicate that further studies on this
class of compounds should be of considerable interest.
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Appendix A. Supplementary data
CCDC 780813 contains the supplementary crystallographic data
for 4a. These data can be obtained free of charge via http://
www.ccdc.cam.ac.uk/conts/retrieving.html, or Cambridge Crystal-
lographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK;
fax: (+44) 1223-336-033; or e-mail: deposit@ccdc.cam.ac.uk.
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